Want to join the conversation?
Marjorie Lopez from Barclays probes on the question of skepticism within the investment community despite a lot of positive signs from the new products. $FIT said that most observers don't understand the company's product strategy. $FIT has a broad line of product where each product addresses a specific need.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?